JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMIPCALABSAILIFENHNEULANDLABACUTAASNATCOPHARM
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Inventory Days (DIO)224.70235.44273.38
Receivable Days (DSO)71.9675.9668.72
Payable Days (DPO)159.32182.81156.40
Cash Conversion Cycle (days)137.34128.59185.70
Working Capital Turnover3.483.011.76
Asset Turnover0.870.920.83
Cash Conversion (CFO/Net Income)1.451.370.99
CFO/EBITDA0.890.870.64
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.